# Relapsed/Refractory Follicular Lymphoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/relapsed-refractory-follicular-lymphoma

> 2 upcoming FDA catalysts in Relapsed/Refractory Follicular Lymphoma: Yescarta (axicabtagene ciloleucel, GILD) on October 2030 (primary completion); Yescarta (axicabtagene ciloleucel, GILD) on Oct 2030 to Jan 2031 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 2030 | [Yescarta (axicabtagene ciloleucel) primary completion](https://sec-api.dev/pdufa/axicabtagene-ciloleucel) | GILD | Relapsed/Refractory Follicular Lymphoma | scheduled | "NCT05371093 (Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05371093)) |
| Oct 2030 to Jan 2031 | [Yescarta (axicabtagene ciloleucel) topline data readout](https://sec-api.dev/pdufa/axicabtagene-ciloleucel) | GILD | Relapsed/Refractory Follicular Lymphoma | scheduled | "NCT05371093 (Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05371093)) |

## Drugs

- [Yescarta (axicabtagene ciloleucel)](https://sec-api.dev/pdufa/axicabtagene-ciloleucel) (GILD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/relapsed-refractory-follicular-lymphoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Relapsed/Refractory Follicular Lymphoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/relapsed-refractory-follicular-lymphoma

```bibtex
@misc{secapidev_indications_relapsed_refractory_follicular_lymphoma_20261116,
  title        = {Relapsed/Refractory Follicular Lymphoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/relapsed-refractory-follicular-lymphoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_relapsed_refractory_follicular_lymphoma_20261116","title":"Relapsed/Refractory Follicular Lymphoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/relapsed-refractory-follicular-lymphoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
